DIME PROJECT

Optimizing direct-to-patient strategies for pharma

Direct-to-patient (DTP) models are changing how patients access care.

Virtual prescribing, digital pharmacies, and direct distribution have created new pathways to treatment, particularly in areas where traditional access has been limited by cost, geography, or system capacity.

Rapid growth is also raising important questions about oversight, clinical marketing standards, and accountability. Recent scrutiny of fast-scaling DTP models has made clear that expanding access and earning patient trust are not automatic outcomes. They require deliberate infrastructure.

We are launching this project to expand direct access to therapies in ways that are safe, compliant, and worthy of patient trust.

Direct-to-patient (DTP) models are changing how patients access care.

Alongside our partners, we will create a practical blueprint for DTP models.

Map the market, regulatory, and policy landscape and translate findings into clear, actionable guidance for teams operationalizing DTP models

Define how to measure patient access and affordability in ways that support transparency and equity

Establish a structured framework for assessing DTP model appropriateness, grounded in regulatory readiness, patient benefit, and commercial viability

Surface real-world examples from across the ecosystem, highlighting both successful and cautionary approaches, with a focus on what drives access, affordability, and sustained patient trust